We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-6.18%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$20.6B
AUM Growth
-$2.22B
Cap. Flow
+$62.6M
Cap. Flow %
0.3%
Top 10 Hldgs %
83.49%
Holding
126
New
5
Increased
17
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
TRDA icon
Entrada Therapeutics
TRDA
+$114M
2
INCY icon
Incyte
INCY
+$108M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$46.7M
4
TSVT
2seventy bio
TSVT
+$26M
5
TVTX icon
Travere Therapeutics
TVTX
+$17.7M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$66.1M
2
FLGT icon
Fulgent Genetics
FLGT
+$17.5M
3
BLUE
bluebird bio
BLUE
+$16M
4
MIRM icon
Mirum Pharmaceuticals
MIRM
+$12.9M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.19%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KZR
101
DELISTED
Kezar Life Sciences
KZR
$2.33M 0.01%
13,968
– –
BNR
102
Burning Rock Biotech
BNR
$93M
$1.99M 0.01%
20,913
– –
CYPH
103
Cypherpunk Technologies Inc
CYPH
$64M
$1.81M 0.01%
55,971
– –
HOOK
104
DELISTED
HOOKIPA Pharma
HOOK
$1.63M 0.01%
70,048
– –
GMDA
105
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$1.55M 0.01%
610,626
– –
SERA icon
106
Sera Prognostics
SERA
$80.3M
$1.39M 0.01%
201,562
– –
NEXI
107
DELISTED
NexImmune, Inc. Common Stock
NEXI
$1.36M 0.01%
11,765
– –
TARA icon
108
Protara Therapeutics
TARA
$214M
$1.35M 0.01%
199,671
– –
OYST
109
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$1.12M 0.01%
61,424
– –
LOGC
110
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$1.04M 0.01%
451,478
– –
FHTX icon
111
Foghorn Therapeutics
FHTX
$278M
$1.03M 0.01%
+45,027
New +$647K
EVFM
112
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$1.01M ﹤0.01%
179,807
– –
SRZNW icon
113
Surrozen Inc Warrant
SRZNW
$36.6K
$958K ﹤0.01%
833,333
– –
PASG icon
114
Passage Bio
PASG
$14.5M
$744K ﹤0.01%
5,858
– –
INZY
115
DELISTED
Inozyme Pharma
INZY
$730K ﹤0.01%
106,999
– –
BLCM
116
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$371K ﹤0.01%
249,123
– –
AUPH icon
117
Aurinia Pharmaceuticals
AUPH
$1.95B
– –
-520,523
Closed -$11.5M
MIRM icon
118
Mirum Pharmaceuticals
MIRM
$6.56B
– –
-647,313
Closed -$12.9M
MREO
119
Mereo BioPharma
MREO
$48.9M
– –
-292,692
Closed -$708K
AMYT
120
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
– –
-518,380
Closed -$6.24M
XLRN
121
DELISTED
Acceleron Pharma
XLRN
– –
-22,430
Closed -$3.86M
1 2 3 4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2021 Portfolio in Review

As of Q4 2021, Baker Bros. Advisors held 126 positions worth $20.6B, down 9.7% from $22.8B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Baker Bros. Advisors's Q4 2021 filing shows 5 new, 17 increased, 8 reduced and 5 closed positions. Its largest new stake was Entrada Therapeutics: 4,704,419 shares worth $80.5M. The largest sale was Seagen Inc. Common Stock, an estimated $66.1M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q4 2021 buy was Entrada Therapeutics: 4,704,419 shares worth $80.5M.
  • Baker Bros. Advisors added most to Incyte in Q4 2021, an estimated $108M increase.
  • Baker Bros. Advisors's biggest Q4 2021 reduction was Seagen Inc. Common Stock, cutting an estimated $66.1M.
  • Baker Bros. Advisors fully exited Mirum Pharmaceuticals in Q4 2021, selling an estimated $12.9M.
  • Baker Bros. Advisors's ten largest holdings make up 83% of its $20.6B portfolio in Q4 2021.
  • Baker Bros. Advisors opened 5 new positions and closed 5 in Q4 2021.
  • Baker Bros. Advisors's portfolio value fell 9.7% quarter-over-quarter to $20.6B.

Based on Baker Bros. Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.